The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of ...

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R for its lead asset Axpaxli for the eye disorder wet age-related macular ...

Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration ... (migaldendranib MGB/D-4517.2) for AMD and DME. Presented at: Retina World ...

The seven-month enrollment for LUGANO represents one of the fastest enrolling Phase 3 pivotal trials for wet AMD to date. LUGANO is the first of two pivotal non-inferiority trials underway in the ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings presented at the ARVO meeting from a phase 2b study evaluating suprachoroidal axitinib for neovascular age-related macular ...

After seeing these MythBusters test results from the swing robot, you might dry off your golf ball a little more often.

Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects SOL-1, Ocular’s first registrational trial in wet AMD, completed randomization in ...

Advanced Micro Devices stock (NASDAQ:AMD) increased by more than 4% during Tuesday's trading session and has risen by nearly 20% over the last month. What factors are contributing to the stock's ...

The data from the phase 2 PRISM study comes from a cohort of 51 patients with wet or neovascular AMD, a form of the disease where abnormal blood vessels grow in the back of the eye. They all had ...

SOL-1, Ocular’s first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 ...

When AMD launched its Ryzen processors on a newly minted AM4 socket in 2017, it was a game changing moment. Finally, AMD was bringing back real competition to Intel. But while Ryzen was killing ...